These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38305253)

  • 1. Milvexian: A Focus on a New Oral Anticoagulant that Targets Factor XIa for Thromboembolism Prophylaxis.
    Birchansky J; Frishman WH
    Cardiol Rev; 2024 Feb; ():. PubMed ID: 38305253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
    Sharma M; Molina CA; Toyoda K; Bereczki D; Bangdiwala SI; Kasner SE; Lutsep HL; Tsivgoulis G; Ntaios G; Czlonkowska A; Shuaib A; Amarenco P; Endres M; Yoon BW; Tanne D; Toni D; Yperzeele L; von Weitzel-Mudersbach P; Sampaio Silva G; Avezum A; Dawson J; Strbian D; Tatlisumak T; Eckstein J; Ameriso SF; Weber JR; Sandset EC; Goar Pogosova N; Lavados PM; Arauz A; Gailani D; Diener HC; Bernstein RA; Cordonnier C; Kahl A; Abelian G; Donovan M; Pachai C; Li D; Hankey GJ
    Lancet Neurol; 2024 Jan; 23(1):46-59. PubMed ID: 38101902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Milvexian for the Prevention of Venous Thromboembolism.
    Weitz JI; Strony J; Ageno W; Gailani D; Hylek EM; Lassen MR; Mahaffey KW; Notani RS; Roberts R; Segers A; Raskob GE;
    N Engl J Med; 2021 Dec; 385(23):2161-2172. PubMed ID: 34780683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.
    Sharma M; Molina CA; Toyoda K; Bereczki D; Kasner SE; Lutsep HL; Tsivgoulis G; Ntaios G; Czlonkowska A; Shuaib A; Amarenco P; Endres M; Diener HC; Gailani D; Kahl A; Donovan M; Perera V; Li D; Hankey GJ
    J Stroke Cerebrovasc Dis; 2022 Oct; 31(10):106742. PubMed ID: 36037679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the Potential Clinical Benefits of Small Molecule Factor XIa Inhibitors in Arterial Thrombosis.
    Wichaiyo S; Parichatikanond W; Visansirikul S; Saengklub N; Rattanavipanon W
    ACS Pharmacol Transl Sci; 2023 Jul; 6(7):970-981. PubMed ID: 37470020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
    Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
    Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis.
    Wang X; Li Q; Du F; Shukla N; Nawrocki AR; Chintala M
    TH Open; 2023 Apr; 7(2):e97-e104. PubMed ID: 37101592
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor.
    Perera V; Wang Z; Lubin S; Christopher LJ; Chen W; Xu S; Seiffert D; DeSouza M; Murthy B
    Cardiol Ther; 2022 Sep; 11(3):407-419. PubMed ID: 35641780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
    Perera V; Wang Z; Luettgen J; Li D; DeSouza M; Cerra M; Seiffert D
    Clin Transl Sci; 2022 Feb; 15(2):330-342. PubMed ID: 34558200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.
    Perera V; Abelian G; Li D; Wang Z; Zhang L; Lubin S; Chen W; Bello A; Murthy B
    Clin Pharmacokinet; 2022 Jun; 61(6):857-867. PubMed ID: 35262846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.
    Wong PC; Crain EJ; Bozarth JM; Wu Y; Dilger AK; Wexler RR; Ewing WR; Gordon D; Luettgen JM
    J Thromb Haemost; 2022 Feb; 20(2):399-408. PubMed ID: 34752670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
    Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
    Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
    Shoamanesh A; Mundl H; Smith EE; Masjuan J; Milanov I; Hirano T; Agafina A; Campbell B; Caso V; Mas JL; Dong Q; Turcani P; Christensen H; Ferro JM; Veltkamp R; Mikulik R; De Marchis GM; Robinson T; Lemmens R; Stepien A; Greisenegger S; Roine R; Csiba L; Khatri P; Coutinho J; Lindgren AG; Demchuk AM; Colorado P; Kirsch B; Neumann C; Heenan L; Xu L; Connolly SJ; Hart RG;
    Lancet; 2022 Sep; 400(10357):997-1007. PubMed ID: 36063821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor.
    Perera V; Wang Z; Lubin S; Christopher LJ; Chen W; Xu S; Seiffert D; DeSouza M; Murthy B
    Sci Rep; 2022 Dec; 12(1):22239. PubMed ID: 36564395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asundexian: an oral small molecule factor XIa inhibitor for the treatment of thrombotic disorders.
    D'Allesandro N; Cave B; Hough A
    Future Cardiol; 2023 Aug; 19(10):477-486. PubMed ID: 37830334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors.
    Jones A; Al-Horani RA
    Med Sci (Basel); 2023 Aug; 11(3):. PubMed ID: 37606428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
    Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
    JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.
    Smith EE; Shoamanesh A; Xu L; Heenan L; Saad F; Colorado P; Chen CH; Lemmens R; De Marchis GM; Caso V; Masjuan J; Hirano T; Milanov I; Campbell BCV; Mas JL; Connolly SJ; Mundl H; Hart RG;
    Stroke; 2024 Feb; 55(2):392-402. PubMed ID: 38174569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Oral Factor XIa Inhibitors in Stroke Prevention: A Systematic Review and Meta-Analysis.
    Palaiodimou L; Papagiannopoulou G; Katsanos AH; Eleftheriou A; Karapanayiotides T; Mitsias PD; Lemmens R; Molina CA; Alexandrov A; Caso V; Shoamanesh A; Sharma M; Tsivgoulis G
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.